Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366171855> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4366171855 endingPage "S122" @default.
- W4366171855 startingPage "S122" @default.
- W4366171855 abstract "Atopic dermatitis (AD) is an allergic disease mediated by Th2 cells. In AD, externally stimulated keratinocytes release inflammatory cytokines, such as IL-33 and TSLP. Inflammatory cells infiltrate skin tissue and increase vascular permeability. Therefore, we hypothesized that imatinib mesylate (IMT), which suppresses vascular permeability, may be a candidate therapeutic agent for AD. To prove this hypothesis, a vitamin D3 analog (MC903) was administered daily to both ears of Balb / c mice to create a murine AD model to which IMT was applied. The skin lesions were evaluated histopathologically and by immunostaining. Cytokine expression in the skin was assessed by using real time polymerase chain reaction (PCR) and immunostaining and was investigated using Evans Blue to determine whether IMT suppressed vascular permeability due to histamine. The suppressive effect of TNF-α/IL-4-induced TSLP expression in primary mouse keratinocytes (MKCs) treated with IMT was then investigated. TSLP gene and protein expression in the lesion was measured using real time PCR and ELISA. The activation of signal transduction was analyzed by western blotting. According to the above experiments, topical application of IMT significantly reduced ear thickness, Evans blue leakage, and scratch onset. IMT suppressed the number of infiltrating cells (CD4+ T cells, eosinophils, basophils) and the expression of IL-13, IL-33, and TSLP in a MC903-induced, murine AD model and inhibited TNF-α/IL-4-induced TSLP expression via downregulation of ERK phosphorylation in MKCs. From the results of this experiment, IMT reduced the skin symptoms in a MC903-induced, murine AD model, suggesting that it may have potential as a new treatment for AD." @default.
- W4366171855 created "2023-04-19" @default.
- W4366171855 creator A5003267153 @default.
- W4366171855 creator A5014357562 @default.
- W4366171855 creator A5047151401 @default.
- W4366171855 creator A5083111988 @default.
- W4366171855 creator A5087264119 @default.
- W4366171855 creator A5087297320 @default.
- W4366171855 creator A5089656042 @default.
- W4366171855 date "2023-05-01" @default.
- W4366171855 modified "2023-09-28" @default.
- W4366171855 title "707 Topical application of imatinib mesylate suppresses vitamin D3 analog-induced dermatitis in balb/c mice" @default.
- W4366171855 doi "https://doi.org/10.1016/j.jid.2023.03.716" @default.
- W4366171855 hasPublicationYear "2023" @default.
- W4366171855 type Work @default.
- W4366171855 citedByCount "0" @default.
- W4366171855 crossrefType "journal-article" @default.
- W4366171855 hasAuthorship W4366171855A5003267153 @default.
- W4366171855 hasAuthorship W4366171855A5014357562 @default.
- W4366171855 hasAuthorship W4366171855A5047151401 @default.
- W4366171855 hasAuthorship W4366171855A5083111988 @default.
- W4366171855 hasAuthorship W4366171855A5087264119 @default.
- W4366171855 hasAuthorship W4366171855A5087297320 @default.
- W4366171855 hasAuthorship W4366171855A5089656042 @default.
- W4366171855 hasBestOaLocation W43661718551 @default.
- W4366171855 hasConcept C1122143 @default.
- W4366171855 hasConcept C134018914 @default.
- W4366171855 hasConcept C164027704 @default.
- W4366171855 hasConcept C203014093 @default.
- W4366171855 hasConcept C204232928 @default.
- W4366171855 hasConcept C2776914184 @default.
- W4366171855 hasConcept C2777649898 @default.
- W4366171855 hasConcept C2778070265 @default.
- W4366171855 hasConcept C2778690821 @default.
- W4366171855 hasConcept C4224716 @default.
- W4366171855 hasConcept C71924100 @default.
- W4366171855 hasConceptScore W4366171855C1122143 @default.
- W4366171855 hasConceptScore W4366171855C134018914 @default.
- W4366171855 hasConceptScore W4366171855C164027704 @default.
- W4366171855 hasConceptScore W4366171855C203014093 @default.
- W4366171855 hasConceptScore W4366171855C204232928 @default.
- W4366171855 hasConceptScore W4366171855C2776914184 @default.
- W4366171855 hasConceptScore W4366171855C2777649898 @default.
- W4366171855 hasConceptScore W4366171855C2778070265 @default.
- W4366171855 hasConceptScore W4366171855C2778690821 @default.
- W4366171855 hasConceptScore W4366171855C4224716 @default.
- W4366171855 hasConceptScore W4366171855C71924100 @default.
- W4366171855 hasIssue "5" @default.
- W4366171855 hasLocation W43661718551 @default.
- W4366171855 hasOpenAccess W4366171855 @default.
- W4366171855 hasPrimaryLocation W43661718551 @default.
- W4366171855 hasRelatedWork W1822726093 @default.
- W4366171855 hasRelatedWork W2038011147 @default.
- W4366171855 hasRelatedWork W2069935301 @default.
- W4366171855 hasRelatedWork W2077917566 @default.
- W4366171855 hasRelatedWork W2083700293 @default.
- W4366171855 hasRelatedWork W2120131335 @default.
- W4366171855 hasRelatedWork W2240106681 @default.
- W4366171855 hasRelatedWork W2591764090 @default.
- W4366171855 hasRelatedWork W2735573692 @default.
- W4366171855 hasRelatedWork W2944325699 @default.
- W4366171855 hasVolume "143" @default.
- W4366171855 isParatext "false" @default.
- W4366171855 isRetracted "false" @default.
- W4366171855 workType "article" @default.